Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733990 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
A Phase 1 study, sponsored by Faron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 216
- Enrollment target
NCT03733990: Completed Phase 1 study, sponsored by Faron Pharmaceuticals.
NCT03733990 is a Phase 1 study that has completed, run by Faron Pharmaceuticals. The registered enrollment target is 216 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (260% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03733990, a Phase 1 study, has completed, sponsored by Faron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 216 participants
- Enrollment target
Study Summary
This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity. The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.
Primary Outcome
Tolerable dose(s) will be determined by the TITE-CRM based on the occurrence/non-occurrence of dose limiting toxicities in the trial subjects.
Interventions
- BIOLOGICAL FP-1305 (bexmarilimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 1 |
What the finished NCT03733990 record still lists
NCT03733990 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (260% higher).
The record links to 0 conditions, and to 1 intervention - of which FP-1305 (bexmarilimab) is the first listed.
NCT03733990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03733990 about?
NCT03733990 is a clinical study titled "A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)". This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates ...
What is the current status of trial NCT03733990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2018-12-03. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT03733990?
The interventions under investigation include: FP-1305 (bexmarilimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03733990?
This trial is sponsored by Faron Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03733990's enrollment target sits among peer trials
216 243rd of 2000 higher than 1,758 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI